Who benefits from percutaneous closure of patent foramen ovale vs medical therapy for stroke prevention? In-depth and updated meta-analysis of randomized trials
Authors:
- 26 April 2019
- journal article
- research article
- Vol. 11 (4) , 126-136
Abstract
BACKGROUND A few randomized clinical trials (RCT) and their meta-analyses have found patent foramen ovale closure (PFOC) to be beneficial in prevention of stroke compared to medical therapy. Whether the benefit is extended across all groups of patients remains unclear. AIM To evaluate the efficacy and safety of PFOC vs medical therapy in different groups of patients presenting with stroke, we performed this meta-analysis of RCTs. METHODS Electronic search of PubMed, EMBASE, Cochrane Central, CINAHL and ProQuest Central and manual search were performed from inception through September 2018 for RCTs. Ischemic stroke (IS), transient ischemic attack (TIA), a composite of IS, TIA and systemic embolism (SE), mortality, major bleeding, atrial fibrillation (AF) and procedural complications were the major outcomes. Random-effects model was used to perform analyses. RESULTS Meta-analysis of 6 RCTs including 3560 patients showed that the PFOC, compared to medical therapy reduced the risk of IS [odds ratio: 0.34; 95% confidence interval: 0.15- 0.78; P = 0.01] and the composite of IS, TIA and SE [0.55 (0.32-0.93); P = 0.02] and increased the AF risk [4.79 (2.35-9.77); P < 0.0001]. No statistical difference was observed in the risk of TIA [0.86 (0.54-1.38); P = 0.54], mortality [0.74 (0.28-1.93); P = 0.53] and major bleeding [0.81 (0.42-1.56); P = 0.53] between two strategies. Subgroup analyses showed that compared to medical therapy, PFOC reduced the risk of stroke in persons who were males, = 45 years of age and had large shunt or atrial septal aneurysm. CONCLUSION In certain groups of patients presenting with stroke, PFOC is beneficial in preventing future stroke compared to medical therapy.Keywords
This publication has 17 references indexed in Scilit:
- Device Closure of Patent Foramen Ovale After StrokeJACC, 2016
- Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic AttackStroke, 2014
- Amplatzer PFO Occluder Device may Prevent Recurrent Stroke in Patients with Patent Foramen Ovale and Cryptogenic Stroke: A Meta-Analysis of Randomised TrialsHeart, Lung and Circulation, 2014
- Initial clinical experience with the Coherex FlatStent™ and FlatStent™ EF PFO closure system for in‐tunnel PFO closure: Results of the Coherex‐EU studyCatheterization and Cardiovascular Interventions, 2013
- Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trialsEuropean Heart Journal, 2013
- Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic StrokeNew England Journal of Medicine, 2013
- Percutaneous Closure of Patent Foramen Ovale in Cryptogenic EmbolismNew England Journal of Medicine, 2013
- Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen OvaleNew England Journal of Medicine, 2012
- Atrial Fibrillation following Device Closure of Patent Foramen OvaleCardiology, 2008
- Patent Foramen Ovale and Cryptogenic Stroke in Older PatientsNew England Journal of Medicine, 2007